Navigation Links
New study finds anticipating a laugh reduces our stress hormones
Date:4/7/2008

SAN DIEGO, CA In 2006 researchers investigating the interaction between the brain, behavior, and the immune system found that simply anticipating a mirthful laughter experience boosted health-protecting hormones. Now, two years later, the same researchers have found that the anticipation of a positive humorous laughter experience also reduces potentially detrimental stress hormones. According to Dr. Lee Berk, the study teams lead researcher of Loma Linda University, Loma Linda, CA, Our findings lead us to believe that by seeking out positive experiences that make us laugh we can do a lot with our physiology to stay well.

In their earlier work the researchers found that the anticipation of mirthful laughter had surprising and significant effects. Two hormones beta-endorphins (the family of chemicals that alleviates depression) and human growth hormone (HGH; which helps with immunity) increased by 27 and 87 percent respectively when volunteers anticipated watching a humorous video. There was no such increase among the control group who did not anticipate watching the humor film.

Using a similar protocol, the current research found that the same anticipation of laughter also reduced the levels of three stress hormones. Cortisol (termed the stress hormone), epinephrine (also known as adrenaline) and dopac, a dopamine catabolite (brain chemical which helps produce epinephrine), were reduced 39, 70 and 38 percent, respectively (statistically significant compared to the control group). Chronically released high stress hormone levels can weaken the immune system.

The research is entitled Cortisol and Catecholamine Stress Hormone Decrease Is Associated with the Behavior of Perceptual Anticipation of Mirthful Laughter. It was conducted by Lee Berk with Stanley A. Tan, both of the Oak Crest Health Research Institute, Loma Linda, CA; and Dottie Berk, Loma Linda University Health Care, Loma Linda. Lee Berk is presenting the teams finding
'/>"/>

Contact: Donna Krupa
DKrupa@the-aps.org
619-525-6202
American Physiological Society
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New study shows Dermytol produces pronounced decrease in malignant melanoma tumor volume
2. 1/3 of risk for dementia attributable to small vessel disease, autopsy study shows
3. New study shows that fetal cells to treat Parkinsons disease may not function long term
4. Yale study shows how rare genes have big impact on blood pressure
5. NASA launches airborne study of arctic atmosphere, air pollution
6. Some migratory birds cant find success in urban areas, study finds
7. Study finds concerns with biofuels
8. Veterinary college researcher studying brain tumors in people and animals
9. Statistics are insufficient for study of proteins signal system
10. Bear spray a viable alternative to guns for deterring bears, BYU study shows
11. Multi-institutional study identifies new form of inherited risk of cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... from around the world will gather in Boston Nov. ...ets and Cancer Therapeutics International Conferen...on important cancer therapies in development. , ...ctively we need a greater understanding of the act...id Lewis Cantley, Ph.D., director of the cancer ce...
(Date:11/8/2009)...ne through deletion of genetic material on chromos...s in learning and behavior, said a consortium of r....bcm.edu ) in a report that appears online today i...h goes about 95 percent of the way to pinning thes...his gene," said Dr. Arthur L. Beaudet ( http://www...
(Date:11/6/2009)... of the publication of On the Origin of Species, t...) is publishing open access two peer-reviewed arti...s into evolution. , The two articles are by Kevin... and James T. Costa of Western Carolina University...n," appeared in the October issue of the AIBS jour...
Breaking Biology News(10 mins):Developmental delay could stem from nicotinic receptor deletion 2Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 4938 1Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 4938 2Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 4938 3Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 4938 4Martek Announces Third Quarter 2009 Financial Results 56082 1Martek Announces Third Quarter 2009 Financial Results 56082 2Martek Announces Third Quarter 2009 Financial Results 56082 3Martek Announces Third Quarter 2009 Financial Results 56082 4Martek Announces Third Quarter 2009 Financial Results 56082 5Martek Announces Third Quarter 2009 Financial Results 56082 6Martek Announces Third Quarter 2009 Financial Results 56082 7Martek Announces Third Quarter 2009 Financial Results 56082 8Martek Announces Third Quarter 2009 Financial Results 56082 9Martek Announces Third Quarter 2009 Financial Results 56082 10Martek Announces Third Quarter 2009 Financial Results 56082 11Martek Announces Third Quarter 2009 Financial Results 56082 12Gentiva 28R 29 Health Services Completes Acquisition of Home Health Agency 56080 1Gentiva 28R 29 Health Services Completes Acquisition of Home Health Agency 56080 2Gentiva 28R 29 Health Services Completes Acquisition of Home Health Agency 56080 3
...he length of nectar spurs--the long tubes leading ...owers to match the tongue lengths of the pollinato... , The researchers were Justen Whittall of the Uni... the University of California at Santa Barbara. Th...(NSF). Their results appear in this week,s issue o...
...ergy and Infectious Diseases (NIAID), a component ...red a survival mechanism in a common type of bacte... bacteria protect itself by warding off attacks fr...e molecules sent by the body to kill bacteria. , B...and gram-negative, with the primary difference bei...
...tations, but just how these mutations contribute t...ew clue comes from scientists at the University of... and Public Health. Their research indicates that ...d, may specifically increase the risk of melanomas...n the NRAS gene, was found in patients who had sun...
Other Biology News:Columbine flowers develop long nectar spurs in response to pollinators 2Newly found sensing system enables certain bacteria to resist human immune defenses 2Sun exposure early in life linked to specific skin cancer gene mutation 2
(Date:11/6/2009)...Austria, November 6 EUCODIS Biosci...ring, and marketing enzymes for the,chemical indus...earch,agreement with Bio Sidus, the leading biopha...he agreement gives EUCODIS Bioscience exclusive ac...Bio Sidus, proprietary collection of,psychrophilic...
(Date:11/6/2009)...if., Nov. 6 Intarcia Therapeutics,...A 650 (DUROS® continuous delivery of exenatid... the Ninth Annual Diabetes Technology Meeting in S....com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,, C...TCA 650 Lowers Plasma Glucose, HbA1c and Reduces W...
(Date:11/5/2009)...Colo., Nov. 5 The endangered black...estern U.S. This rare carnivore feeds on prairie ...lague and often entire population die-offs in town...S) has implemented a ferret breeding program and h...eir formerly native habitat. Unfortunately, plagu...
(Date:11/5/2009)...all on Thursday, November 5, 2009 at 4:30 p.m. Eas.../PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals...XI ) today reported unaudited financial results fo...r 30, 2009 and reviewed the Company,s highlights f...consolidated results reflect the operations of Onc...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
... two-thirds (67%) of Americans are generally conce...pply, according to a 2008 National Consumer Water ...adlines warning of contaminants1 (i.e. lead, radiu... stirred controversy and confusion. Consumers are ...le plastic bottles isn’t an environmentally-...
...ex, Inc. ("ChromaDex"),today announced that effect...I Acquisition, Inc. ("CDI"), the wholly-owned subs...tin Board: CDYE). The transaction,enables ChromaDe... publicly,traded, which will help it be better pos...wing marketplace. The business and operations of C...
...ction Agency Contract Will Support Development o...ial Broad-Spectrum Anti-Viral Ag...euticals, Inc. (Nasdaq: PPHM ), a clinical stage ...tibodies for the treatment of cancer and,hepatitis...ntered into a,five-year contract worth up to $44.4...
Other Biology Technology: Culligan's New Aqua-Cleer Advanced Drinking Water SystemProvides Clean, Quality Water Customized for Every Home 2 Culligan's New Aqua-Cleer Advanced Drinking Water SystemProvides Clean, Quality Water Customized for Every Home 3ChromaDex, Inc. Announces Completion of Reverse Merger With Cody Resources, Inc. 2Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 2Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 3Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 4Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers 5
Rabbit Anti-Mouse Junctophilin-4, C-Terminus Monoclonal Antibody, Unconjugated, Clone PADZMD.487 from Invitrogen
...PCR Cloning Kits are designed to speed up the PCR ...s, regardless of sequence or type of polymerase us...ding those that are difficult to clone by other PC...for potentially detrimental proteins can be cloned...
Mounting Medium from BioVision
GeneAmp High Fidelity PCR from Applied Biosystems
Biology Products: